Brief: Neovacs: Biosense Global Exercises Option To Acquire Exclusive License For IFNalpha Kinoid In China

Neovacs SA

11/09/2018 06:25

Sept 11 (Reuters) - NEOVACS SA  ALNEV.PA :
    * REG-NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS
EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR
IFNALPHA KINOID TO TREAT LUPUS IN CHINA
    * NEOVACS WILL RECEIVE A MILESTONE PAYMENT FOLLOWING
EXERCISING OF
OPTION
    * COMPANY CONTINUES TO PURSUE ITS DISCUSSIONS WITH OTHER
POTENTIAL
PARTNERS FOR A GLOBAL LICENSING AGREEMENT
    * BIOSENSE GLOBAL EXERCISED ITS OPTION FOR A GLOBAL VALUE OF
UP TO
65 MILLION EUROS
    * AGREEMENT COVERS DEVELOPMENT AND COMMERCIALIZATION IN
CHINA OF
THERAPEUTIC VACCINE IFNALPHA KINOID FOR INDICATION LUPUS

Source text for Eikon:  ID:nGNE1G4mgr 
Further company coverage:  ALNEV.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))